Peter J. Kushner

Olema Pharmaceuticals (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

49h-index15.0kcitations123works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(96), Retinoids in leukemia and cellular processes(23), Cytokine Signaling Pathways and Interactions(14), Advanced Breast Cancer Therapies(10), Computational Drug Discovery Methods(8)

Publications123 total

Discovery of Palazestrant (OP-1250), a Potent and Orally Bioavailable Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD)
ACS Omega·2025· 1 citedOpen Access
Supplementary Figure S2 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Data from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Table S3 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Table S1 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Legends from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Figure S6 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Methods 1 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Figure S4 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Table S1 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Figure S7 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Table S2 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Figure S4 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Figure S5 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Figure S6 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Figure S1 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Figure S5 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Figure S7 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Data from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
Supplementary Figure S1 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
2024Open Access
page 1 of 7Next →

Frequent Co-authors

Paul Webb(24), Gabriela N. Lopez(12), John D. Baxter(12), Geoffrey L. Greene(9), Brian L. West(9), James W. Apriletti(8), Rosalie M. Uht(8), Weijun Feng(8), Thomas S. Scanlan(7), Robert J. Fletterick(6), Ralff C.J. Ribeiro(6), Stefan Nilsson(5), Michael R. Stallcup(5), Carol M. Anderson(5), Richard G. Pestell(5), Phuong Nguyen(5), Cathleen D. Valentine(4), Chenguang Wang(4), Fred Schaufele(4), Leslie Hodges-Gallagher(4)